These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 20686407)
1. Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy. Lee JL; Eun Kim J; Ahn JH; Lee DH; Lee J; Kim CS; Hyuk Hong J; Hong B; Song C; Ahn H Am J Clin Oncol; 2011 Apr; 34(2):140-4. PubMed ID: 20686407 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518 [TBL] [Abstract][Full Text] [Related]
4. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Fizazi K; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houedé N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Lagrange JL; Chinet-Charrot P; Linassier C; Deplanque G; Beuzeboc P; Geneve J; Davin JL; Tournay E; Culine S Eur J Cancer; 2012 Jan; 48(2):209-17. PubMed ID: 22119204 [TBL] [Abstract][Full Text] [Related]
5. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. Taplin ME; Xie W; Bubley GJ; Ernstoff MS; Walsh W; Morganstern DE; Regan MM J Clin Oncol; 2006 Dec; 24(34):5408-13. PubMed ID: 17135641 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Italiano A; Ortholan C; Oudard S; Pouessel D; Gravis G; Beuzeboc P; Bompas E; Fléchon A; Joly F; Ferrero JM; Fizazi K Eur Urol; 2009 Jun; 55(6):1368-75. PubMed ID: 18706755 [TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. Sella A; Sternberg CN; Skoneczna I; Kovel S BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177 [TBL] [Abstract][Full Text] [Related]
8. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Nakabayashi M; Xie W; Buckle G; Bubley G; Ernstoff MS; Walsh W; Morganstern DE; Kantoff PW; Taplin ME Urology; 2013 Mar; 81(3):611-6. PubMed ID: 23452809 [TBL] [Abstract][Full Text] [Related]
10. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707 [TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer. Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314 [TBL] [Abstract][Full Text] [Related]
13. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757 [TBL] [Abstract][Full Text] [Related]
14. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy. Du J; Yang Q; Chen XS; Tian J; Yao X Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138 [TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542 [TBL] [Abstract][Full Text] [Related]